Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation. Issue 5 (27th February 2018)

• Record Type: Journal Article
• Authors: Zhao, Wanli; Zhou, Xudong; Qi, Guisong; Guo, Yuexian
• Is Part Of: Journal of biochemical and molecular toxicology. Volume 32:Issue 5(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-02-27
• Subjects: curcumin -- epigenetic regulation -- histone acetylation -- JNK -- prostate cancer; Biochemistry -- Periodicals; Molecular biology -- Periodicals; Toxicology -- Periodicals; 574
• DOI: 10.1002/jbt.22049
• Languages: English
• ISSNs: 1095-6670

Abstract

Abstract: Curcumin is a component of turmeric and is isolated from the rhizomes of the plant Curcuma longa . Curcumin was reported to have therapeutic effects on prostate cancer. Yet the molecular mechanism of curcumin remains unclear. In this study, mouse prostate cancer xenograft model was established and subjected to curcumin treatment. GST‐c‐Jun pull down kinase assays were performed to study the phospho‐c‐Jun level. Cell Counting Kit‐8 assay kit was utilized to detect the cell viability. Immunoblotting and qRT‐PCR were performed for target gene expression analysis. Curcumin inhibited growth of prostate cancer in vivo as well as promoted apoptosis of LNCaP cells in vitro. Curcumin inhibited JNK pathway and repressed H3K4me3 in LNCaP cells. Combined use of curcumin and JQ‐1 inhibited the prostate cancer efficiently. In conclusion, curcumin inhibits JNK pathway and plays a role in epigenetic regulation of prostate cancer cells by repressing H3K4me3.